Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes (TotCamp)

The University of Texas System (UT)

Status

Completed

Conditions

Type 1 Diabetes Mellitus

Treatments

Behavioral: Intensive Education

Study type

Interventional

Funder types

Other

Identifiers

NCT02432586

STU 042014-061

Details and patient eligibility

About

18 preschool aged children and their families will attend structured, multidisciplinary, family-centered intensive education sessions over a 3-day weekend in a residential camp setting to address the unique challenges of managing type 1 diabetes mellitus in young children. A second 'booster' session, will be conducted 6 months later.

Full description

We propose to deliver a structured multidisciplinary family-centered intervention over a 3-day weekend, with a second similar "booster" session 6 months later. The intervention will be based at our regional diabetes camp, Camp Sweeney. The proposed camp encounters aim to provide:

An opportunity for intensive education beyond that achievable in a single class, and without the unfavorable impacts of multiple weekday classes on family and work time.
Varied educational modalities including didactic sessions, practical demonstrations and role playing.
Close observation of each child throughout the day and night by experienced diabetes counselors and medical staff to identify and help correct maladaptive family behaviors.
A safe environment where parents can participate in group therapy sessions without child care worries.
An opportunity for age-appropriate child-centered educational and therapeutic activities.
An opportunity for families to form mutually-supportive friendships.
Fun weekends away where the parents have help caring for their diabetic children.

We will conduct this pilot study, which will enroll 18 preschool children age 3-5.5 years, with the goal of obtaining preliminary results for 15 subjects.

The primary outcome, to be determined approximately one month before and after each of the two camp sessions, is improvement in Hemoglobin A1c (HbA1c). This outcome will be compared with that of historical controls.

Exploratory Hypotheses:

Compared with pretreatment baseline and historical controls, subjects attending two 3-day sessions at a family diabetes camp will improve:

HbA1c 3 months after the first camp session
Hypoglycemia frequency, as measured by continuous glucose monitoring
Medical system utilization, as measured by telephone call frequency and also by emergency room visits and hospitalizations
Behavioral/QoL assessments, including the parents of young children version of the hypoglycemia fear survey (HFS-P-YC), the Behavioral Pediatrics Feeding Assessment Scale (BPFAS), and the general and diabetes modules of the PedsQL.
Diabetes knowledge, assessed by questionnaire
Development of friendships between subject families, assessed by questionnaire

Enrollment

18 patients

Sex

All

Ages

34 to 68 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 3-5.5 years old (+/- 2 months) at the date of first camp session they are eligible to join.
Child and Parents fluent in either English or Spanish.
Type 1 diabetes mellitus diagnosed for at least 10 months previous to date of first camp they are eligible to join.
Taking insulin
Custodial parent or guardian (preferable both parents or guardians) willing to attend both session of camp and the activities scheduled for them.
Parent or guardian must sign consent before any study procedures are performed.

Exclusion criteria

Neonatal diabetes (diagnosis in the first 3 months of life) or documented MODY; i.e., a likely genetic form of diabetes rather than an autoimmune etiology.
Post-surgical diabetes (e.g., pancreatectomy for congenital hyperinsulinism). Such patients often cannot secrete glucagon, leading to a particularly severe inability to defend against hypoglycemia.
Other severe chronic disease (e.g., cancer, cystic fibrosis) which in the judgment of the investigator is likely to significantly affect glycemic control.
Patients cannot be taking systemic corticosteroids at enrollment because of adverse effects on glycemic control, but we will not disqualify subjects who require such therapy during the study. Inhaled or topical corticosteroids are permissible.
Patients with hypothyroidism or hyperthyroidism must be clinically euthyroid and have free T4 and TSH within age-appropriate reference ranges at last medically indicated testing. Patients with out of range values may be retested after medication dose adjustment.
Developmental delay or behavioral disorder in the patient of sufficient severity, in the judgment of the investigator, to interfere with group activities.
Medical or psychiatric disorder in a parent of sufficient severity, in the judgment of the investigator, to interfere with group activities.
Celiac disease is not an exclusion criterion.